Innogenetics

Fujirebio Acquires ADx Neurosciences and Confirms Its Intentions to Bring Better and Earlier Neurodegenerative Disease Diagnostic Solutions to the Global Diagnostics Industry

Retrieved on: 
Thursday, June 23, 2022
Finance, Neurology, Genetics, Clinical Trials, Professional Services, Stem Cells, Other Health, Biotechnology, General Health, Health, Antibody, Â, Solution, Industry, Neurodegeneration, CSF, Innogenetics, CEO, IVD, Neuroscience, CDMO, Research, TSE, Disease, Prognosis, ADX, Acquisition, Plasma, Biomarker, Tokyo Stock Exchange, Patient, Organization, Medical imaging, Vaccine, Fujirebio

Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros.

Key Points: 
  • Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros.
  • We are excited to work together with the ADx NeuroSciences team to expand the global neurodegeneration biomarker testing market.
  • ADx NeuroSciences specializes in generating tailor-made antibodies and developing assays for pharma and in vitro diagnostics (IVD) companies.
  • Fujirebio is a trusted partner for high-quality IVD testing solutions and a historical pioneer in neurodegenerative disease diagnostics.

Fujirebio Confirms Its Engagement in Blood-based Alzheimer’s Disease Biomarker Testing with the Launch of the Fully Automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma Assays for Research Use Only

Retrieved on: 
Wednesday, March 30, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Fujirebio, Biomarker, Organization, Neurodegeneration, Plasma, Diagnosis, Neuro, IVD, Research, Innogenetics, Amyloid, CEO, Laboratory, Tau, Cerebrospinal fluid, CSF, Medical device

Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G -Amyloid 1-42 Plasma and Lumipulse G -Amyloid 1-40 Plasma assays for the fully automated LUMIPULSE G immunoassay systems.

Key Points: 
  • Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G -Amyloid 1-42 Plasma and Lumipulse G -Amyloid 1-40 Plasma assays for the fully automated LUMIPULSE G immunoassay systems.
  • These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of -amyloid1-42 and -amyloid1-40 in human plasma within just 35 minutes.
  • The two new automated blood-based biomarker assays are available for Research Use Only.
  • These four CSF parameters can provide essential information on the presence of amyloid and tau pathology in neurodegenerative disease.

Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only

Retrieved on: 
Tuesday, March 1, 2022
Mental Health, Medical Supplies, Medical Devices, Health, Clinical Trials, Biotechnology, Partnership, Amyloid, Diagnosis, Neurodegeneration, Research, Industry, Organization, Innogenetics, MacKenzie Scott, Biomarker, Charles, Tau, Alzheimer's disease, Dementia, Fujirebio, AD, Patient, CSF, Cerebrospinal fluid, IVD, Association, Program, CEO, Plasma, Pharmaceutical industry, Medical imaging, Medical device, Dolby Laboratories, Fujirebio, the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation, FUJIREBIO, THE DIAGNOSTICS ACCELERATOR AT THE ALZHEIMER’S DRUG DISCOVERY FOUNDATION

Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 181 Plasma assay for the fully automated LUMIPULSE G immunoassay systems.

Key Points: 
  • Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 181 Plasma assay for the fully automated LUMIPULSE G immunoassay systems.
  • This CLEIA (chemiluminescent enzyme immunoassay) assay allows for the quantitative measurement of Tau phosphorylated at threonine 181 in human plasma within just 35 minutes.
  • With the launch of this new neurodegeneration assay, automated blood-based biomarker testing for Alzheimers disease (AD), and testing for plasma pTau 181 in particular, may soon transition from research to clinical routine2.
  • The Lumipulse G pTau 181 Plasma assay complements the panel of four key cerebrospinal fluid (CSF) assays (A1-42, A1-40, tTau and pTau 181) already available on the LUMIPULSE G platform.

Fujirebio Europe Receives Translational Research Funding From Alzheimer’s Drug Discovery Foundation for Development of a Fully Automated Plasma pTau181 Testing Solution

Retrieved on: 
Thursday, October 28, 2021
Managed Care, Pharmaceutical, Philanthropy, Consumer, Mental Health, Foundation, Science, Cardiology, Biotechnology, Seniors, Other Science, Health, Diagnosis, Tau, Research, Efficiency, Blood, Neurodegeneration, Association, Organization, Alzheimer's disease, MacKenzie Scott, Dementia, Innogenetics, CSF, Alzheimer's Drug Discovery Foundation, Christiaan De Wilde, CEO, Biomarker, IVD, Charles, Plasma, Pharmaceutical industry, Medical device

Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE G immunoassay platform.

Key Points: 
  • Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE G immunoassay platform.
  • pTau is recognized as an important fluid biomarker linked to the diagnosis of Alzheimers disease (AD).
  • Access to a fully automated Lumipulse G plasma pTau181 assay will allow clinicians and clinical research professionals to measure plasma pTau181 levels with a high degree of precision and efficiency.
  • These span the range from specialized testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.

Global Oncology Molecular Diagnostics Market Report 2020-2030: Major Players are Abbott Diagnostics, BD, Cepheid, Danaher, Beckman Coulter, Leica Biosystems, Gen Probe, Qiagen, Roche, Siemens

Retrieved on: 
Wednesday, February 17, 2021
Companies, Organizations, Medical software, Qiagen, Cepheid, Molecular diagnostics, Danaher Corporation, Roche Diagnostics, Leica Biosystems, Beckman Coulter, Innogenetics

Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.

Key Points: 
  • Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.
  • The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.
  • Therefore, the high cost of molecular diagnostic tests is expected to hamper the growth of the oncology molecular diagnostics market.
  • Global Oncology Molecular Diagnostics Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.

The Chinese In Vitro Diagnostics Market is Forecast to Reach USD 22.3 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 5, 2021
Health, General Health, Medical tests, Medicine, IVD, Point-of-care testing, In vitro, Health sciences, Innogenetics

The "China In Vitro Diagnostics (IVD) Market, By Segment (Clinical Chemistry, Immunoassay, Molecular Testing, Microbiology, Hematology, SMBG, POCT, Coagulation) and Companies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China In Vitro Diagnostics (IVD) Market, By Segment (Clinical Chemistry, Immunoassay, Molecular Testing, Microbiology, Hematology, SMBG, POCT, Coagulation) and Companies" report has been added to ResearchAndMarkets.com's offering.
  • The 21st century brought a rapid development in China's IVD industry, where all the tools such as reagents and instruments are produced in-house.
  • According to this report, China's In Vitro Diagnostics Market will be USD 22.3 Billion by 2026.
  • This report studies the China IVD Industry and is broken down as follows:
    By Segment - The Report Studies the Market of the following 8 Categories:

13th Edition Report on the Worldwide Market for In Vitro Diagnostic Tests to 2025 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 15, 2020
Health, Other Health, IVD, In vitro, Medical tests, Innogenetics

1500 + Page Report Based on Vendor Reporting, Interviews, Vendor Activities

Key Points: 
  • 1500 + Page Report Based on Vendor Reporting, Interviews, Vendor Activities
    Coverage of Growth Markets: Eastern Europe and the Middle East, and Southeast Asia
    The Worldwide Market for In Vitro Diagnostic (IVD) Tests estimates the current In Vitro diagnostics market size and forecasted market size to 2025 for defined segments of the IVD market and various sub-segments, including:
    Microbiology and Virology by Test Type (Immunoassays, ID/AST, Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies)
    For each of the listed In Vitro diagnostics market segments, 2019 In Vitro diagnostics market size, 2025 projection and compound annual growth rate is provided, as well as significant In Vitro diagnostic companies in the market and IVD manufacturers' product innovations.
  • The market data is put into a context with real-world industry and medical practice trends.
  • The Worldwide Market for In Vitro Diagnostic Tests has been called "The Bible of the IVD Industry" by customers, which include top IVD firms.
  • Using the The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 13th Edition, ensures that your firm will have the perspective and data of others in the in vitro diagnostics industry, as well as of those who track and invest in the IVD industry.

The 80-Billion Dollar IVD Market: Five Fast Facts from New Report

Retrieved on: 
Monday, September 14, 2020
IVD, Cision, Companies, Innogenetics

ARLINGTON, Va., Sept. 14, 2020 /PRNewswire-PRWeb/ --Kalorama Information recently released its report on the 80+ billion dollar in vitro diagnostic market.

Key Points: 
  • ARLINGTON, Va., Sept. 14, 2020 /PRNewswire-PRWeb/ --Kalorama Information recently released its report on the 80+ billion dollar in vitro diagnostic market.
  • 2) IVD Influences $8 Trillion+ Dollars of Other Markets: While the IVD market is large enough on its own, IVD industry also influences other markets.
  • Markets for clinical lab services, biotech research and healthcare IT are also influenced by what happens in in vitro diagnostics.
  • Due to perfection of production, expert distribution and acquisition of companies, a select group of companies dominate IVD.

Co-Diagnostics, Inc. Logix Smart™ COVID-19 Test Authorized for Use in Australia

Retrieved on: 
Friday, August 7, 2020
Biotechnology, Medical tests, Molecular diagnostics, Life sciences, Biology, Branches of biology, IVD, Cepheid Inc, Innogenetics

Australia joins the United States, India, Mexico, the European Community and others as a region where the Company's test can be sold and used as a coronavirus in vitro diagnostic (IVD).

Key Points: 
  • Australia joins the United States, India, Mexico, the European Community and others as a region where the Company's test can be sold and used as a coronavirus in vitro diagnostic (IVD).
  • The Australian Government Register of Therapeutic Goods Certificate was recently issued to the Company's distributor in Australia, approving the distributor to supply the Class 3 IVD to the Australian market.
  • Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology.
  • The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA).

Fujirebio Diagnostics Announces Initiation of Clinical Testing for the Fully Automated Lumipulse® SARS CoV-2 Antigen Assay

Retrieved on: 
Wednesday, August 5, 2020
Research, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, Medical Supplies, Practice Management, FDA, Other Science, Health, Natural sciences, Chemistry, Immunologic tests, Physical sciences, Biochemistry methods, Enzyme immunoassay, Immunoassay, Assay, Emergency Use Authorization, Medical laboratory, Innogenetics, Fujirebio Diagnostics, Inc., Fujirebio

Group Holdings, Inc., announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration.

Key Points: 
  • Group Holdings, Inc., announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration.
  • The Lumipulse SARS-CoV-2 Antigen assay will be available for use on the LUMIPULSE G1200 instrument.
  • The LUMIPULSE G1200 is a robust, fully automated CLEIA (chemiluminescent enzyme immunoassay) immunoassay instrument.
  • Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.